CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Shares of vaccine-makers fell after reports that Donald Trump is expected to nominate vaccine skeptic Robert F. Kennedy Jr.

Moderna ( MRNA )—most shorted—saw short interest rise to 10.02% from 9.14% in September. Cencora ( COR) came in second with a ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...